Related Experiment Videos
P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy
N Baldini1, K Scotlandi, M Serra
1Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, University of Bologna, Italy. nicola.baldini@ior.it
Summary
P-glycoprotein expression in osteosarcoma predicts treatment response. High expression indicates resistance to doxorubicin, suggesting a need for tailored chemotherapy for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- P-glycoprotein (P-gp) expression is a known prognostic indicator in osteosarcoma treated with multi-agent chemotherapy.
- P-glycoprotein is implicated in drug resistance, particularly with doxorubicin, a key agent in osteosarcoma treatment.
Purpose of the Study:
- To investigate the prognostic significance of P-glycoprotein expression in osteosarcomas treated solely with doxorubicin and surgery.
- To determine if P-glycoprotein expression correlates with the tumor's response to doxorubicin-based therapy.
Main Methods:
- Immunohistochemistry was used to assess P-glycoprotein expression in 37 operable, nonmetastatic osteosarcoma specimens.
- P-glycoprotein status was analyzed against event-free survival in patients receiving doxorubicin as a single adjuvant drug.
Main Results:
- Widespread P-glycoprotein expression at diagnosis was significantly linked to increased systemic relapse rates (p < 0.001).
- Comparison with a multi-agent chemotherapy cohort showed that only P-gp-positive, doxorubicin-resistant tumors benefited from non-doxorubicin agents (p < 0.001).
Conclusions:
- Osteosarcoma's response to adjuvant chemotherapy can be predicted by P-glycoprotein expression at diagnosis.
- P-glycoprotein status can guide risk-adapted, individualized therapeutic strategies, differentiating between standard and intensive approaches.